ArticleFrontiers in cell and developmental biology2021
Tetramethylpyrazine Improves Cognitive Impairment and Modifies the Hippocampal Proteome in Two Mouse Models of Alzheimer's Disease.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Catalpol and tetramethylpyrazine relieve Alzheimer's disease by facilitating AQP4 protein expression and polarized distribution in hippocampal astrocytes via inducing the STAT3-mediated UCHL1 expression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ginsenoside Rg1 Ameliorates the Learning and Memory Deficits of 5xFAD Mice by Inhibiting CCR3 Activity: Insights from In Vivo and In Vitro Investigations.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Exploring neuroprotective effects of Chuanzhitongluo capsule on an alzheimer's disease rat model.Metabolic brain disease · 2025Article
- From a traditional medicine monomer to a modern neurotherapeutic scaffold: a review of SAR-Driven tetramethylpyrazine derivatives for cerebrovascular and cognitive health.Frontiers in pharmacology · 2025Review
- Study on the improvement of cognitive deficits in APP/PS1 mice by danggui shaoyao san and its disassembled prescriptions through modulation of the gut microbiota.Frontiers in microbiology · 2025Article
- Review
- Progress on the Synthesis Pathways and Pharmacological Effects of Naturally Occurring Pyrazines.Molecules (Basel, Switzerland) · 2024Review
- TAT-W61 peptide attenuates neuronal injury through blocking the binding of S100b to the V-domain of Rage during ischemic stroke.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Neuroprotection by tetramethylpyrazine and its synthesized analogues for central nervous system diseases: a review.Molecular biology reports · 2024Review
- Acetylome analyses provide novel insights into the effects of chronic intermittent hypoxia on hippocampus-dependent cognitive impairment.Frontiers in molecular neuroscience · 2024Article
- Article
- Natural products regulate mitochondrial function in cognitive dysfunction-A scoping review.Frontiers in pharmacology · 2023Article
- Increasing brain glucose metabolism by ligustrazine piperazine ameliorates cognitive deficits through PPARγ-dependent enhancement of mitophagy in APP/PS1 mice.Alzheimer's research & therapy · 2022Article
- Regulatory mechanisms of tetramethylpyrazine on central nervous system diseases: A review.Frontiers in pharmacology · 2022Review
- Research progress in traditional Chinese medicine in the treatment of Alzheimer's disease and related dementias.Frontiers in pharmacology · 2022Review
- Redox signaling and metabolism in Alzheimer's disease.Frontiers in aging neuroscience · 2022Review
- A Tau Pathogenesis-Based Network Pharmacology Approach for Exploring the Protections ofFrontiers in pharmacology · 2022Article
- Traditional Chinese Medicine for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2022Review
- The Roles of Tetramethylpyrazine During Neurodegenerative Disease.Neurotoxicity research · 2021Review
- High-fat diet-induced atherosclerosis promotes neurodegeneration in the triple transgenic (3 × Tg) mouse model of Alzheimer's disease associated with chronic platelet activation.Alzheimer's research & therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD), one of the most common neurodegenerative diseases, has no effective treatment. We studied the potential effects of tetramethylpyrazine (TMP), an alkaloid in the rhizome of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.